• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.

作者信息

Ma Hongxia, Zhang Qian, Duan Qianqian, Zhang Qin, Li Fengsen

机构信息

Pneumology Department, The Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi City, The Xinjiang Uygur Autonomous Region, 830000, China.

State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.

出版信息

Lung Cancer. 2021 Feb;152:196-198. doi: 10.1016/j.lungcan.2020.12.015. Epub 2020 Dec 16.

DOI:10.1016/j.lungcan.2020.12.015
PMID:33386152
Abstract
摘要

相似文献

1
Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.在一例肺腺癌中鉴定出一种新型NPM1-ROS1融合基因，且对克唑替尼治疗敏感。
Lung Cancer. 2021 Feb;152:196-198. doi: 10.1016/j.lungcan.2020.12.015. Epub 2020 Dec 16.
2
Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.一名对克唑替尼敏感的微卫星不稳定晚期肺腺癌青少年患者中新型RBPMS-ROS1融合的鉴定：病例报告
Clin Lung Cancer. 2020 Mar;21(2):e78-e83. doi: 10.1016/j.cllc.2019.09.003. Epub 2019 Sep 26.
3
Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.克唑替尼在携带罕见ZCCHC8-ROS1融合基因的肺腺癌中的临床活性
J Thorac Oncol. 2018 Aug;13(8):e148-e150. doi: 10.1016/j.jtho.2018.03.028.
4
A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.综合基因组分析鉴定的肺腺癌新型 CD74-ROS1 融合变异病例，对克唑替尼和恩曲替尼有效。
Thorac Cancer. 2021 Sep;12(18):2504-2507. doi: 10.1111/1759-7714.14093. Epub 2021 Jul 28.
5
Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.鉴定肺腺癌中对克唑替尼敏感的新型 WNK1-ROS1 融合。
Lung Cancer. 2019 Mar;129:92-94. doi: 10.1016/j.lungcan.2018.12.011. Epub 2018 Dec 19.
6
Response to Crizotinib After Entrectinib Resistance in -Rearranged, -Amplified Lung Adenocarcinoma.克唑替尼耐药后对 -重排、-扩增肺腺癌的反应。
JCO Precis Oncol. 2024 Oct;8:e2400394. doi: 10.1200/PO-24-00394. Epub 2024 Oct 7.
7
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.ROS1-ADGRG6：肺腺癌中一种新型 ROS1 致癌融合变异的病例报告及对克唑替尼的反应。
BMC Cancer. 2019 Aug 5;19(1):769. doi: 10.1186/s12885-019-5948-y.
8
Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.获得性 MET D1228N 突变介导 ROS1 融合肺腺癌对克唑替尼的耐药：一例报告。
Oncologist. 2021 Mar;26(3):178-181. doi: 10.1002/onco.13545. Epub 2020 Oct 28.
9
First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.一线克唑替尼与铂类培美曲塞化疗用于晚期 ROS1 重排非小细胞肺癌患者。
Cancer Med. 2020 May;9(10):3310-3318. doi: 10.1002/cam4.2972. Epub 2020 Mar 13.
10
Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy.一名接受克唑替尼治疗的ROS1重排肺腺癌患者出现进行性干咳。
JAMA Oncol. 2021 Jan 1;7(1):124-125. doi: 10.1001/jamaoncol.2020.2809.

引用本文的文献

1
Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel Fusion.病例报告：一名携带新型融合基因的转移性肺腺癌患者对一线克唑替尼单药治疗的短期反应
Front Oncol. 2022 Apr 28;12:862008. doi: 10.3389/fonc.2022.862008. eCollection 2022.